PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of springeropenLink to Publisher's site
General Thoracic and Cardiovascular Surgery
 
Gen Thorac Cardiovasc Surg. 2017; 65(3): 153–159.
Published online 2016 October 25. doi:  10.1007/s11748-016-0724-2
PMCID: PMC5331109

A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy

Abstract

Objectives

Pulmonary endarterectomy (PEA) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but postoperative residual hypertension leads to in-hospital mortality. Inhaled epoprostenol sodium (PGI2) and NO are administered for pulmonary hypertension after cardiothoracic surgery. This prospective study provides the first comparative evaluation of the effects of inhaled PGI2 and NO on pulmonary hemodynamics, systemic hemodynamics, and gas exchange in patients developing residual pulmonary hypertension after PEA.

Methods

Thirteen patients were randomized to receive either NO (n = 6) or PGI2 (n = 7) inhalation when pulmonary hypertension persisted after weaning from cardiopulmonary bypass. Hemodynamic and respiratory variables were measured before inhalation of the agent (T0); 30 min (T1), 3 h (T2), and 6 h after inhalation (T3); and the next morning (T4). The NO dose was started at 20 ppm and gradually tapered until extubation, and PGI2 was administered at a dose of 10 ng kg−1 min−1.

Results

In both groups, mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) significantly decreased over time until T4 (mean PAP: p < 0.0001; PVR: p = 0.003), while mean systemic arterial blood pressure significantly increased (p = 0.028). There were no significant between-group differences in patient characteristics, cardiac index, left atrial pressure, or ratio of arterial oxygen tension to fraction of inspired oxygen. There were no in-hospital deaths.

Conclusions

Both inhaled PGI2 and NO significantly reduced PAP and PVR without adverse effects on systemic hemodynamics in patients who developed residual pulmonary hypertension after PEA. Inhaled PGI2 can be offered as alternative treatment option for residual pulmonary hypertension.

Keywords: Chronic thromboembolic pulmonary hypertension, Pulmonary endarterectomy, Residual pulmonary hypertension, Inhaled prostacyclin, Inhaled nitric oxide

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by pulmonary artery obstruction with organized thrombus and small vascular remodeling in the muscular pulmonary arteries, leading to pulmonary hypertension and right heart failure [1]. Although medical treatment is ineffective and palliative, pulmonary endarterectomy (PEA), which aims for complete removal of organized thrombus with the vascular intima, can provide excellent long-term outcomes with substantial improvement of pulmonary hypertension and symptoms, and is thus a potentially curative treatment of CTEPH [24]. However, PEA has a steep learning curve and requires meticulous postoperative management. In-hospital mortality rates after PEA still remain high (up to 7%), although experienced PEA centers can provide better results [2, 3, 5, 6]. Residual pulmonary hypertension occurs in up to 10% of patients and is significantly associated with in-hospital mortality [2, 5].

Optimal treatment of residual pulmonary hypertension after PEA requires pulmonary vasodilator agents with effective reduction of pulmonary artery pressure (PAP) and improvement of hypoxemia, without worsening systemic hypotension. Inhalation of short-acting vasodilator agents, including prostacyclin (PGI2) [7] and nitric oxide (NO) [8], has been proposed as a treatment option for this complication. Inhaled NO has been a preferred treatment for pulmonary hypertension and right ventricular dysfunction in patients who underwent cardiac surgery [9, 10]. However, the effect of inhaled NO for residual pulmonary hypertension after PEA is still controversial [11]. A randomized control trial of inhaled NO in patients who underwent PEA demonstrated no favorable effects on reperfusion lung edema, duration of mechanical ventilation, or perioperative mortality [12]. In contrast, inhaled iloprost, an aerosolized prostacyclin analogue, significantly reduced PAP, pulmonary vascular resistance (PVR), and increased cardiac output in patients who underwent PEA [7]. These results prompted us to compare the effectiveness of both drugs on residual pulmonary hypertension after PEA. In this prospective study, we sought to evaluate the effects of inhaled PGI2 and NO on pulmonary hemodynamics, systemic hemodynamics, and gas exchange in patients who developed residual pulmonary hypertension after PEA.

Materials and methods

This prospective, randomized, observational study was approved by the institutional ethics committee on human research of Chiba University, and informed consent was obtained from each patient. Consecutive patients who underwent elective PEA at our hospital between Jan 2013 and June 2014 were enrolled. Inclusion criteria of this study were patients who developed residual pulmonary hypertension immediately after weaning from cardiopulmonary bypass. Residual pulmonary hypertension was defined as mean PAP (mPAP) above 25 mmHg despite proper treatment within 30 min after weaning from cardiopulmonary bypass. Exclusion criteria were patients who had relief of pulmonary hypertension (mPAP below 25 mmHg) after PEA (n = 3), and those who developed excessive pulmonary hemorrhage (n = 2), and severe residual pulmonary hypertension requiring extracorporeal membrane oxygenation (n = 1). Although it was difficult to predict which patients would develop residual pulmonary hypertension, preoperative mPAP are shown to be associated with postoperative high mPAP [4]. So the objective of dynamic stratified randomization by computer is to ensure balance of the both groups with respect to preoperative mPAP and PVR. Patients were registered by the Patient Registration Center System.

Surgery and postoperative management

All patients underwent right heart catheterization and pulmonary angiography for a definitive diagnosis of CTEPH, and operability was assessed by a CTEPH team. An inferior vena cava filter (Günther-Tulip®Vena Cava Filter, Cook Medical Inc., Bloomington, IN, USA) was placed prior to the surgery in all patients. PEA was performed via a median sternotomy and under periods of deep hypothermic circulatory arrest, according to a protocol of the University of California, San Diego [2]. An arterial line was placed in both the femoral artery and the radial artery to monitor systemic arterial pressure. A Swan-Ganz catheter (Baxter Healthcare Corp., Deerfield, IL) was introduced to continuously monitor pulmonary artery and central venous pressure, as well as cardiac output (Vigilance Monitor, Baxter Healthcare Corp.). During cardiopulmonary bypass, a left atrial catheter was placed via the right upper pulmonary vein to monitor left atrial pressure and administer norepinephrine to maintain systemic arterial pressure without vasoconstriction of the pulmonary arteries. Epinephrine was administered via a central venous catheter, if necessary. Catecholamine was adjusted to maintain the mean femoral arterial pressure above 60 mmHg. No vasodilator agents were intravenously administered. The baseline ventilator setting at weaning from cardiopulmonary bypass was as follows: oxygen fraction = 1.0, positive end-expiratory pressure (PEEP) = 10 cmH2O, and tidal volume = 6–8 mL/kg. Mechanical ventilator settings were adjusted to maintain PaO2 above 80 mmHg and PaCO2 < 40 mmHg. Patients were sedated with propofol and mechanically ventilated with high PEEP until the next morning. Negative water balance was maintained through the aggressive administration of diuretics. Reperfusion lung edema was defined as hypoxemia (PaO2/FiO2 ratio < 300) accompanied by a new lung infiltrate on chest X-ray in an area that had been reperfused, without another cause for the hypoxemia or acute chest radiograph abnormality.

Protocols

After weaning from cardiopulmonary bypass, the preload and dose of catecholamine were optimized and ventilator stings were adjusted to treat hypoxemia and hypercapnia. If pulmonary hypertension persisted above 25 mmHg, pulmonary vasodilator inhalation therapy was indicated. Thirteen patients were randomized to receive either NO (n = 6) or PGI2 (n = 7) following a randomization list edited by the institutional Clinical Study Coordination Center, whose members were unaware of the patients’ identities. The patients continuously inhaled each agent until extubation or the point at which mPAP decreased below 25 mmHg. The patients were not blinded to the inhaled agent because only one drug delivery system was mounted at a time on the ventilator. The hemodynamic and respiratory variables were measured before inhalation of the agent (T0); 30 min (T1), 3 h (T2), and 6 h after inhalation (T3); and on the next morning (T4). Side effects attributable to the use of the agents were recorded, including methemoglobinemia and excessive chest drain bleeding due to platelet dysfunction. Methemoglobin was measured every 6 h with a blood oximeter (ABL 700 series; Radiometer, Copenhagen, Denmark). To avoid rebound pulmonary hypertension after the withdrawal of No inhalation, No doses were gradually decreased before extubation.

Studied agents

PGI2 group: epoprostenol sodium (FLOLAN, epoprostenol sodium injection, prostacyclin; GlaxoSmithKline LLC, Brentford, United Kingdom) was continuously inhaled in a dose of 10 ng kg−1 min−1. For aerosolization of epoprostenol, we connected a jet nebulizer (AeroNeb Pro; Aerogen, Galway, Ireland) to a ventilator (Puritan BennettTM 840 Ventilator; Covidien, Minneapolis, MN). The nebulizer chamber (Cirrus; Intersurgical, Twickenham, United Kingdom) was connected to the inspiratory limb 10 cm from the endotracheal tube. We dissolved 1.5 mg of epoprostenol in glycine buffer diluent (sterile diluent for FLOLAN) to obtain a concentration of 15,000 ng/mL. Epoprostenol solution was continuously delivered at a constant rate of 20 mL/h during intubation.

NO group: NO was supplied in cylinders as 10,000 parts per million (ppm) of NO in nitrogen (Woikoski, Voikoski, Finland). We used a Nomius C blender system (Nomius C, version 1.2; Gävle, Sweden) to deliver NO into the breathing circuit of the ventilator. Inspired NO and nitrogen dioxide (NO2) concentration were monitored continuously using a Nomius C chemiluminescence analyzer. NO inhalation started at 20 ppm.

Statistical analysis

The results are expressed as means ± standard deviations. Continuous variables were compared via the Mann–Whitney U test, and categorical data were compared via the Chi-square test. Analysis of variance for repeated measures was used to detect differences between the PGI2 and NO groups for the effects of drug, time, hemodynamic conditions, and respiratory conditions. In case of a significant interaction, time × group comparison was performed using Tukey’s method. Differences were considered significant for two-sided p values less than 0.05. All statistical analyses were performed using JMP® 12 (SAS Institute Inc., Cary, NC).

Results

Baseline patient characteristics are shown in Table 1. There were no significant differences in preoperative pulmonary hemodynamics or hypoxemia between the two groups. Mean duration of cardiopulmonary bypass (PGI2: 352 ± 67 versus NO: 347 ± 20 min; p = 0.87) and deep hypothermic circulatory arrest (PGI2: 47 ± 9 versus NO: 47 ± 11 min; p = 0.92) were also comparable. There was no in-hospital mortality and no patient developed methemoglobinemia, excessive chest drain bleeding, rebound pulmonary hypertension, or systemic hypotension requiring cessation of the drugs during the study period. However, 2 patients (1 patient in each group) developed late tamponade. Extubation was performed on postoperative day 2 for 2 patients in the PGI2 group who had excessive positive balance during the postoperative period, as well as one patient who developed reperfusion lung edema in the NO group. The other patients were extubated on postoperative day 1.

Table 1
Preoperative patient characteristics

The figures show the pulmonary hemodynamics, PaO2/FiO2 ratio (Fig. 1) and systemic hemodynamics (Fig. 2) during the study period. Mean PAP (PGI2: 34.7 ± 5.0 versus NO: 34.1 ± 6.0 mmHg; p = 0.87) and PVR (PGI2: 717 ± 127 versus NO: 699 ± 354 dyne s cm−5; p = 0.91) at T0 were comparable between the groups. After induction of the agents, mPAP and PVR significantly decreased over time until T4 (mPAP: p < 0.0001 and PVR: p = 0.003), although there were no significant statistical differences between the groups. Mean PAP and PVR at T4 were similar in both groups (PGI2: 28.7 ± 4.8 versus NO: 24.7 ± 6.9 mmHg; p = 0.27, and PG: 481 ± 98 versus NO: 373 ± 147 dyne s cm−5; p = 0.15). Despite residual pulmonary hypertension at the time of weaning from cardiopulmonary bypass, 2 patients in the PGI2 group and 4 patients in the NO group had no residual pulmonary hypertension the next morning. The PaO2/FiO2 ratio in the PG group appeared to be higher at T2, but the difference was not statistically significant (Fig. 1). Mean systemic pressure (mBP) significantly increased over time until T4 (p = 0.028). Cardiac index and left atrial pressure were stable and comparable between the groups during the study period (Fig. 2). Water balance was compared during the surgery and the postoperative period, which lasted from admission to the intensive care unit until the next morning. Patients in the No group had a trend toward having a more positive water balance during the surgery (PGI2: 3074 ± 1523 versus No: 5633 ± 2923 mL; p = 0.08). However, there was no statistically significant difference between the groups on the morning of the next day (PGI2: 185 ± 1045 versus No: −471 ± 1028 mL; p = 0.27).

Fig. 1
Changes in mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) and ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FIO2 ratio) at each time point in the PGI2 (mesh) and No groups (white). Variables were measured ...
Fig. 2
Changes in systemic hemodynamics: mean systemic arterial blood pressure (mBP), cardiac index and left atrial pressure at each time point in the PGI2 (mesh) and NO groups (white). Variables were measured before inhalation of the agent (T0); 30 min ...

There were no statistically significant differences between the groups at 1 year after the surgery: mPAP (PGI2: 28.0 ± 3.6 versus NO: 28.4 ± 3.3 mmHg; p = 0.93), cardiac index (PGI2: 2.96 ± 0.1 versus NO: 2.7 ± 0.1 mmHg; p = 0.26) and PVR (PGI2: 399.3 ± 68.1 versus NO: 360.4 ± 63.1 dyne s cm−5; p = 0.68). All patients in both groups preoperatively administered oral PH drug: PDE5 inhibitors, ET receptor antagonists and prostanoids. Four patients (PGI2: 3 patients versus NO: 1 patient) postoperatively improved mPAP and discontinued medications; however, the others were postoperatively treated with soluble guanylate cyclase. There were no patients treated with BPA in both groups.

Discussion

The leading cause of in-hospital mortality after PEA is residual pulmonary hypertension, which can be attributed to several pathological factors, including residual thrombus due to incomplete PEA, small vessel disease in the muscular arteries, induction of inflammatory reaction, and ischemia reperfusion injury to the lung [13, 14]. Patients may develop residual pulmonary hypertension even in cases of successful PEA, which aims at complete removal of all organized thrombus in the segmental and subsegmental arteries. Among the factors that may be responsible for residual pulmonary hypertension, small vessel disease has an important relationship with the structural pathology of CTEPH. Small vessel disease is caused by chronic exposure of vascular components to high pressure and shear stress, and can be responsible for residual pulmonary hypertension after PEA [15]. PEA is an invasive procedure that requires a prolonged duration of cardiopulmonary bypass and periods of deep hypothermic circulatory arrest. Surgical trauma and cardiopulmonary bypass induce inflammatory reactions by activating inflammatory cytokines and vasoconstrictive mediators. In addition, removal of the organized thrombus causes ischemia reperfusion injury to the lung, and the inflammatory reaction further exacerbates the injury and progresses to reperfusion lung edema [13]. In particular, in cases with less than mild to moderate residual pulmonary hypertension, pulmonary vasodilator medicines can exacerbate lung edema; however, inhalation therapy with NO or PGI2 did not adversely affect reperfusion lung edema, since this study showed improved P/F ratio at T1 and T2 in both groups. Furthermore, to prevent reperfusion lung edema, we avoided high cardiac output by reducing cardiac preload, which sometimes have resulted in systemic hypotension. We attempted at maintaining mBP above 60 mmHg by means of noradrenaline administration. Patients in PGI2 had lower LAP and higher mBP at T1 compared with the baseline, which may indicate low cardiac preload and vasoconstriction due to noradrenaline.

Inhaled NO has been the preferred treatment in patients with pulmonary hypertension who undergo cardiothoracic surgery [9, 10, 16, 17]. However, there is some controversy regarding whether inhaled NO is clinically effective after PEA. A randomized control trial of inhaled NO did not reduce reperfusion lung edema, the duration of mechanical ventilation, or perioperative mortality [12]. In contrast, another crossover study of inhaled NO in patients who underwent PEA showed significant improvements of mPAP (baseline: 22.8 ± 6.2 versus during NO: 21.2 ± 5.0 mmHg; p < 0.05) and PVR index (baseline: 312 ± 98 versus during NO: 277 ± 93 dyne s cm−5; p < 0.01) 12 h after the surgery, although there were no significant differences 3 h after the surgery [8]. On the other hand, inhaled PGI2 has been examined extensively in light of the disadvantages of inhaled NO, and favorable evidence has been obtained. Wet et al. showed a significant decrease in mPAP from 35 ± 9 to 24 ± 8.4 mmHg 6 h after the induction of continuous inhalation of epoprostenol in patients who underwent cardiothoracic surgery [18]. Hache et al. showed that single inhalation of epoprostenol significantly decreased mPAP from 32 ± 9 to 28 ± 8 mmHg in patients with pulmonary hypertension undergoing cardiac surgery [19]. In patients who underwent PEA, Kramm et al. showed that a high dose of inhaled iloprost significantly decreased mPAP as compared with placebo, with a mean decrease of 11 ± 1.1 mmHg [7].

The present study showed that both inhaled PGI2 and NO reduced PAP and PVR without leading to deteriorated systemic circulation, thus indicating that inhaled PGI2 can be an alternative agent to NO in the treatment of residual pulmonary hypertension after PEA. Previous studies evaluating the effects of inhaled PGI2 and NO demonstrated that the outcomes of inhaled PGI2 were similar to or even better than the outcomes of NO [2022]. A randomized crossover study revealed favorable effects of both inhaled epoprostenol and NO on pulmonary hemodynamics and cardiac output in heart and lung transplant patients [21]. In another randomized study of inhaled iloprost and NO in patients with pulmonary hypertension who underwent cardiac surgery, both agents significantly reduced mPAP, reduced PVR, and increased cardiac output, but inhaled iloprost showed significant greater improvements [22]. In addition, the combination therapy of inhaled NO and PGI2 has additive effects on pulmonary hemodynamics [23]. A successful combination therapy was also reported in a case of residual pulmonary hypertension after PEA [24].

The main limitation of this study is the small number of analyzed patients, which is attributable to the relative rarity of the operation. Furthermore, this study is not a confirmatory phase III trial, but an exploratory randomized phase II trial. The purpose of the trial is to evaluate the safety and efficacy and to determine whether to perform a subsequent phase III trial. Although the number of our patients enrolled in this study was small, we conducted a post hoc power analysis; with n = 16 patients, the study was designed to detect differences in mean values corresponding to an effect size of 1.1 with a power of 80% when applying the Student’s t test at a significance level of 0.20. In addition, the present study did not include a placebo group or a dose–response assessment for different doses of PGI2 and NO; these additional investigations were not undertaken because residual pulmonary hypertension is associated with high in-hospital mortality after PEA. The dose of epoprostenol (10 ng kg−1 min−1) in this study might have been smaller than the doses in previous studies (160,000 ng/h), while the dose of inhaled NO (20 ppm) was consistent with previous studies [18, 21]. However, no dose-dependent effect of inhaled epoprostenol (0–50 ng/kg/min) on pulmonary hemodynamics was demonstrated in a study of patients with acute respiratory distress syndrome, while the PaO2/FiO2 ratio improved with the increased dose [25]. Finally, the precise amount of epoprostenol that reaches the alveoli is uncertain because of losses in the nebulizer chamber and ventilator tubing, and may vary between patients.

Conclusion

This prospective, randomized study of inhaled pulmonary vasodilators demonstrated that both inhaled PGI2 and NO significantly reduced PAP and PVR without adverse effects on systemic hemodynamics in patients who developed residual pulmonary hypertension after PEA. Therefore, inhaled PGI2 can be offered as alternative treatment option for residual pulmonary hypertension.

Acknowledgements

We thank Dr. Kengo Ngashima, Ph.D., Department of Global Clinical Research, Graduate School of Medicine, Chiba University, for statistical consultation. This study was partly supported by a Grant to the Pulmonary Hypertension Research Group (No. 27280401) from the Japan Agency for Medical Research and Development, AMED. Funding was provided by 10.13039/100006520 Edwards Lifesciences.

Compliance with ethical standards

Compliance with ethical standards

Conflict of interest

The authors declare that they have no potential conflicts of interest.

References

1. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–2020. doi: 10.1161/CIRCULATIONAHA.105.602565. [PubMed] [Cross Ref]
2. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: experience and lessons learned in 1500 cases. Ann Thorac Surg. 2003;76:1457–1462. doi: 10.1016/S0003-4975(03)00828-2. [PubMed] [Cross Ref]
3. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97–103. doi: 10.1016/j.athoracsur.2012.04.004. [PubMed] [Cross Ref]
4. Ishida K, Masuda M, Tanabe N, Matsumiya G, Tatsumi K, Nakajima N. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2012;144:321–326. doi: 10.1016/j.jtcvs.2011.09.004. [PubMed] [Cross Ref]
5. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702–710. doi: 10.1016/j.jtcvs.2010.11.024. [PubMed] [Cross Ref]
6. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet. 2011;378:1379–1387. doi: 10.1016/S0140-6736(11)61144-6. [PubMed] [Cross Ref]
7. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg. 2005;28:882–888. doi: 10.1016/j.ejcts.2005.09.007. [PubMed] [Cross Ref]
8. Imanaka H, Miyano H, Takeuchi M, Kumon K, Ando M. Effects of nitric oxide inhalation after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism. Chest. 2000;118:39–46. doi: 10.1378/chest.118.1.39. [PubMed] [Cross Ref]
9. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet. 2000;356:1464–1469. doi: 10.1016/S0140-6736(00)02869-5. [PubMed] [Cross Ref]
10. Maxey TS, Smith CD, Kern JA, Tribble CG, Jones DR, Kron IL, et al. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg. 2002;73:529–532. doi: 10.1016/S0003-4975(01)03398-7. [PubMed] [Cross Ref]
11. Potapov E, Meyer D, Swaminathan M, Ramsay M, El Banayosy A, Diehl C, et al. Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. J Heart Lung Transpl. 2011;30:870–878. [PubMed]
12. Parquin F, Auriant J, Chajllot A. The use of NO in prevention of reperfusion edema following pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 2002;165:A18.
13. Jenkins DP, Madani M, Mayer E, Kerr K, Kim N, Klepetko W, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2013;41:735–742. doi: 10.1183/09031936.00058112. [PubMed] [Cross Ref]
14. Kramm T, Eberle B, Krummenauer F, Guth S, Oelert H, Mayer E. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg. 2003;76:711–718. doi: 10.1016/S0003-4975(03)00728-8. [PubMed] [Cross Ref]
15. Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:571–576. doi: 10.1513/pats.200605-113LR. [PubMed] [Cross Ref]
16. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26:15–23. doi: 10.1097/00003246-199801000-00011. [PubMed] [Cross Ref]
17. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation. 2001;72:638–641. doi: 10.1097/00007890-200108270-00013. [PubMed] [Cross Ref]
18. De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127:1058–1067. doi: 10.1016/j.jtcvs.2003.11.035. [PubMed] [Cross Ref]
19. Hache M, Denault A, Belisle S, Robitaille D, Couture P, Sheridan P, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003;125:642–649. doi: 10.1067/mtc.2003.107. [PubMed] [Cross Ref]
20. Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Muhling J, et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg. 2002;22:746–752. doi: 10.1016/S1010-7940(02)00488-8. [PubMed] [Cross Ref]
21. Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009;138:1417–1424. doi: 10.1016/j.jtcvs.2009.04.063. [PubMed] [Cross Ref]
22. Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth. 2008;22:406–413. doi: 10.1053/j.jvca.2007.10.015. [PubMed] [Cross Ref]
23. Antoniou T, Koletsis EN, Prokakis C, Rellia P, Thanopoulos A, Theodoraki K, et al. Hemodynamic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery. J Cardiothorac Vasc Anesth. 2013;27:459–466. doi: 10.1053/j.jvca.2012.07.020. [PubMed] [Cross Ref]
24. Flondor M, Merkel M, Hofstetter C, Irlbeck M, Frey L, Zwissler B. The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy. Anaesthesia. 2006;61:1200–1203. doi: 10.1111/j.1365-2044.2006.04861.x. [PubMed] [Cross Ref]
25. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest. 2000;117:819–827. doi: 10.1378/chest.117.3.819. [PubMed] [Cross Ref]

Articles from Springer Open Choice are provided here courtesy of Springer